New equipment will mean new jobs at Bay firm

Torbay Weekly

Torbay Pharmaceuticals (TP), which is part of Torbay and South Devon NHS Foundation Trust, is investing in new equipment to increase its production capacity and future-proof operations at its Paignton site.

From Torbay Pharmaceuticals’ beginnings, supplying generic pharmaceuticals to Torbay Hospital, TP has grown in size and scope and now employs over 200 people in Paignton and beyond, supplying NHS and private sector pharmaceutical customers regionally, nationally and internationally.

The installation of the new High Speed Vial Line (HSVL) will allow Torbay Pharmaceuticals to increase production capacity, providing opportunities for more skilled jobs locally over the coming years.

The investment is a testament to Torbay Pharmaceuticals’ commitment to the local economy and to delivering a secure supply for all customers, translating to benefit for patients.

Emma Rooth, Managing Director at Torbay Pharmaceuticals, said: “Installing the High-Speed Vial Line is a key milestone in TP’s growth strategy. The HSVL allows us to increase our production capacity, to meet growing patient needs. This investment will create exciting opportunities for local skilled jobs as we continue to develop and respond to the changing demands of the market.”

Liz Davenport, Chief Executive, Torbay and South Devon NHS Foundation Trust, added: “This important investment will see Torbay Pharmaceuticals go from strength to strength, supplying local and national customers across the NHS and beyond. With this new installation, we will see not just benefits for the local NHS but also to the local community with an increase in high quality employment.”

The installation period will begin in March, and the lead contractor is Scitech, a specialist contractor for the pharmaceutical and biotechnology sectors.

Torbay Pharmaceuticals opened their 76,000 square foot manufacturing facility in 2017, the result of a £26m investment.

Today, the manufacturing site supports the needs of customers in 20 countries around the world, supplying terminally sterilised injectable medicines, a range of non-sterile oral liquids and a wide range of ingredients for TPN compounding, both as Torbay Pharmaceutical licensed products and CMO/CDMO manufactured medicines.

Find out more by visiting